ライフサイエンスコーパス: fractional shortening

1 ardiomyocytes (cell shortening) and in vivo (fractional shortening).

2 enhancement of cytosolic calcium levels and fractional shortening.

3 utput, stroke volume, ejection fraction, and fractional shortening.

4 including hypertrophy, fibrosis, and reduced fractional shortening.

5 ction fraction, with a trend toward lower LV fractional shortening.

6 significant decrease in the left ventricular fractional shortening.

7 s and end diastolic pressures, and increased fractional shortening.

8 eceded left ventricular dilation and reduced fractional shortening.

9 ildren had similar low left ventricular (LV) fractional shortening.

10 ft ventricle, with a significant decrease in fractional shortening.

11 LV end diastolic dimension, and no change in fractional shortening.

12 icular (LV) dimension, wall thicknesses, and fractional shortening.

13 size, and modestly impaired left ventricular fractional shortening.

14 hild over the age of 10 months had depressed fractional shortening.

15 ricular end-diastolic diameter and decreased fractional shortening.

16 ith a significant change in left ventricular fractional shortening.

17 ernal diameter at end-diastole and decreased fractional shortening.

18 on of left ventricular ejection fraction and fractional shortening.

19 ft ventricular wall thickness, and decreased fractional shortening.

20 by maintenance of the ejection fraction and fractional shortening.

21 denced by decreases in ejection fraction and fractional shortening.

22 deposition in mouse hearts and a decrease in fractional shortening.

23 ular end diastolic diameter and reduction of fractional shortening.

24 received doxorubicin alone (left ventricular fractional shortening: -0.82, 95% CI -1.31 to -0.33; end

25 nd vehicle (39.2 + or - 2.07%), increased LV fractional shortening 1.25-fold over wild-type MSCs and

26 ion fraction 28.8%+/-9.6% vs. 44.4%+/-11.5%; fractional shortening 12.7%+/-5.1% vs. 23.6%+/-6.2%); ho

27 mals that received placebo had a decrease in fractional shortening (-12+/-12%) (P<0.05).

28 In contrast, myocyte fractional shortening (14.1+/-.9% versus 11.1+/-.9%, P<0

29 pertrophy and displayed a strong decrease in fractional shortening (14.6+/-1.6% versus 27.6+/-1.4% in

30 train (20% versus 23%; P=<0.001) and midwall fractional shortening (15.9% versus 16.7%; P=0.001) were

31 - 0.17 mm vs. 4.19 +/- 0.09 mm, P < 0.005; % fractional shortening, 15 +/- 2 vs. 36 +/- 2, P < 0.005)

32 scores (+4.2 vs. +4.2), and left ventricular fractional shortening (16% vs. 17%) at diagnosis were si

33 g, when there was significant deterioration (fractional shortening 18.3 +/- 2.4% vs. 46.9 +/- 2.6%, p

34 Patients with both fulminant (fractional shortening 19 +/- 4%) and acute myocarditis (

35 5.7+/-0.3 mm, P:<0.001) and showed global (% fractional shortening 19.1+/-2.5 versus 55.3+/-2.2, P:<0

36 2.06; P=0.036), worse left ventricular (LV) fractional shortening (19.7+/-1.5% versus 27.2+/-1.5%, P

37 stitution, improved echocardiography-derived fractional shortening (20.25% and 19.26%, respectively,

38 as significantly better than in MI-controls (fractional shortening 21% versus 16%, P=0.01; fractional

39 e until 16 weeks (ejection fraction, -45.6%; fractional shortening, -22.6%).

40 t-ventricular ejection fraction=45 +/- 2.6%; fractional shortening=22.9 +/- 1.6%; TH = 43% [25%, 45%]

41 ejection fraction (56.2+/-3.5; P=0.029) and fractional shortening (24.3+/-2.1; P=0.03) were improved

42 recovery of 56%; ejection fraction=50+/-1%; fractional shortening=26+/-0.6% at 5 mins, n=3), but was

43 ventricular ejection fraction=51.7 +/- 1.1%; fractional shortening=26.7 +/- 0.7%) than in animals fro

44 tening (ejection fraction %, 54.76 +/- 0.67; fractional shortening %, 27.53 +/- 0.50) compared with s

45 ted with improved left ventricular function (fractional shortening, 28.4% versus 18.8%; P=0.0114), re

46 that received MMP inhibitor had no change in fractional shortening (-3+/-13%), whereas animals that r

47 actile function measured as left ventricular fractional shortening (30 +/- 3% Galpha(q) versus 43 +/-

48 nant myocarditis had dramatic improvement in fractional shortening (30 +/- 8%) compared with no impro

49 WT versus 3.1+/-0.1 mm r/r, P<0.013); better fractional shortening (30+/-2% WT versus 46+/-4% r/r; P<

50 (WT) cardiomyocytes, ARDKO displayed reduced fractional shortening (~33%) and slower relaxation (~20%

51 within 5 mins (ejection fraction=64+/-4% and fractional shortening=36+/-3%, n=6) and heart rate incre

52 infarct area (13.5% +/- 4.1%) and decreased fractional shortening (38% +/- 5%).

53 A mice (ejection fraction %, 71.60 +/- 4.02; fractional shortening %, 39.63 +/- 3.23).

54 Left ventricle fractional shortening (39.1+/-6.2 versus 47.1+/-6.9%) an

55 (MHC) isoform switch and fibrosis, decreased fractional shortening (39.8 +/- 1.4 FA versus 27.9 +/- 1

56 n-induced cardiac hypertrophy with preserved fractional shortening (39.9+/-1.2% versus 25.9+/-2.6% in

57 nesis and maintained functional performance (fractional shortening, 39% versus 25.2% in Puma(-/-) ver

58 ion and depressed systolic function (percent fractional shortening, 39+/-4 versus 23+/-4; P=0.042).

59 tening (ejection fraction %, 73.06 +/- 6.31; fractional shortening %, 42.33 +/- 5.70) compared with s

60 dimensions, and ameliorated the decrease in fractional shortening (42+/-2% versus 34+/-4%).

61 5% in GqTG; P=0.001), which improved percent fractional shortening (43+/-3% versus 27+/-3%; P=0.017),

62 ce showed an improvement in left ventricular fractional shortening (44.3 +/- 13.3% treated versus 37.

63 ntrols (ejection fraction %, 73.57 +/- 0.20; fractional shortening %, 46.75 +/- 0.38).

64 ion (59 %) of isolated papillary muscle, (2) fractional shortening (50 %), amplitude of the Ca(2+) tr

65 with increases in stroke volume (15 [2] mL), fractional shortening (8% [1]), and ejection fraction (7

66 The z scores for LV fractional shortening (a measure of cardiac function) we

67 progressive decline in left ventricular (LV) fractional shortening accompanied by ventricular dilatio

68 Both grafts led to better fractional shortening (AdCMVhBcl-2/mH9c2: 0.21+/-0.03; m

69 left ventricular mass, and left ventricular fractional shortening (adjusted HR, 1.23; 95% CI, 1.09-1

70 or congestive heart failure and decreased LV fractional shortening among those with familial DCM (n=7

71 lsequestrin developed CHF (50.9% decrease in fractional shortening and 56.4% increase in lung weight,

72 LV) mass, wall thickness, contractility, and fractional shortening and above normal LV afterload.

73 sed, with mutant hearts exhibiting decreased fractional shortening and an immature conduction pattern

74 dministration also resulted in a decrease in fractional shortening and an increase in Tei index, sugg

75 ll mouse hearts exhibited a 36% reduction in fractional shortening and an increased diastolic ventric

76 These abnormalities translate into reduced fractional shortening and cardiac contractility at the i

77 Fractional shortening and cardiac output were also signi

78 andard echocardiographic readouts, including fractional shortening and cardiac output, remained uncha

79 tal wall thickness z-scores and increased LV fractional shortening and contractility up to age 2 year

80 9 versus 1.92+/-0.13 microm/s), whereas both fractional shortening and contraction rates are not diff

81 phy revealed significantly increased percent fractional shortening and decreased left ventricular end

82 cardiomyopathy with up to a 65% decrease in fractional shortening and die prematurely.

83 Fractional shortening and dimension at the end of therap

84 entricular mass reduction, and depression of fractional shortening and ejection fraction in tafazzin-

85 howed left ventricular hypertrophy and lower fractional shortening and ejection fraction in VD-defici

86 With candesartan pretreatment, LV fractional shortening and ejection fraction increased (P

87 At 4 weeks, fractional shortening and ejection fraction were determi

88 tion (assessed by preserved left ventricular fractional shortening and ejection fraction) even if inc

89 depressed ventricular function with reduced fractional shortening and ejection fraction, and myocard

90 ic volume and smaller decreases in long-axis fractional shortening and ejection fraction.

91 bnormal cardiac contractility as measured by fractional shortening and ejection fraction.

92 orubicin chemotherapy, mean left ventricular fractional shortening and end-systolic dimension Z score

93 I tissue resulted in significant increase in fractional shortening and improved systolic function.

94 rdiac dysfunction characterized by decreased fractional shortening and interstitial and perivascular

95 both strains had dilated LVs with decreased fractional shortening and lower ejection fractions.

96 ancing age, LV dimensions decreased, whereas fractional shortening and LV wall thickness increased co

97 rogressive dilated cardiomyopathy, decreased fractional shortening and metabolic dysfunction involvin

98 The KD mice had normal fractional shortening and no heart failure, cardiac hype

99 time delayed and progressive improvement in fractional shortening and other measures of ventricular

100 ence of high-perfusate calcium, both myocyte fractional shortening and peak systolic [Ca2+]i were dep

101 failure, mdx-S2808A mice exhibited improved fractional shortening and reduced cardiac dilation.

102 rtrophy, but it significantly improved basal fractional shortening and responsiveness to beta-adrener

103 , GBS subjects also had increased LV midwall fractional shortening and RV fractional area change.

104 ween serial change in both LV mass index and fractional shortening and subsequent cardiac failure per

105 e ACi group 4 weeks after pressure overload, fractional shortening and the rate of left ventricular p

106 e of zSTARS knockdown, resulting in improved fractional shortening and ventricular end-diastolic dime

107 vement in load-dependent (ejection fraction, fractional shortening) and load-independent (preload rec

108 trophy and enhanced contractility (increased fractional shortening) and no signs of heart failure.

109 t failure (as documented by >25% decrease in fractional shortening) and were randomized to receive ei

110 left ventricular end diastolic diameter and fractional shortening, and a dramatic increase of life s

111 ventricular end-diastolic diameter, reduced fractional shortening, and decreased relative wall thick

112 tional parameters such as ejection fraction, fractional shortening, and E/A ratio in the Ad.Trx1-admi

113 ad decreased end-diastolic volume, long-axis fractional shortening, and ejection fraction (0.60+/-0.1

114 both strains of mice had a similar LV size, fractional shortening, and ejection fraction by echocard

115 ed left ventricular end-systolic dimensions, fractional shortening, and ejection fraction in mice wit

116 left-ventricular (LV) hypertrophy, decreased fractional shortening, and increased LV end-diastolic pr

117 rd normal values in LV dimension, afterload, fractional shortening, and mass, but all these parameter

118 Vegetation size, left ventricular fractional shortening, and onset of aortic valvular regu

119 lic blood pressure, LV ejection fraction, LV fractional shortening, and systolic wall thickness were

120 se of left ventricular ejection fraction and fractional shortening, and the decreased levels were sim

121 ACV mice displayed increased heart rates and fractional shortening as assessed by echocardiography.

122 3 (P<0.05), including ejection fraction and fractional shortening as compared with groups 1 and 2.

123 ficantly attenuated DOXO-induced decrease in fractional shortening as measured by blinded echocardiog

124 nt increase in +dL/dt and -dL/dt and greater fractional shortening as measured by edge detection (P<0

125 gnificant hypertrophy, dilation, and reduced fractional shortening, as revealed by gated cardiac MRI

126 vity and a ~30% decrease in cAMP content and fractional shortening associated with a mild cardiac hyp

127 mong infants without HIV infection, the mean fractional shortening at 10 to 14 months was 38.1 percen

128 Among HIV-infected infants, the mean fractional shortening at 10 to 14 months was similar in

129 he level of betaARKct protein expression and fractional shortening at 12 weeks after TAC.

130 ane protection (p=0.04) for left ventricular fractional shortening at 5 years in girls (1.17, 0.24-2.

131 monstrated greater protection of border zone fractional shortening at 6 weeks.

132 In multivariate modeling, fractional shortening at the endocardium (relative risk

133 ase, confidence interval [CI] 1.27 to 2.39), fractional shortening at the midwall (RR 1.29 per five-u

134 al improvement measured by echocardiography (fractional shortening at week 4: 27.2+/-1.3% versus 22.3

135 LV systolic and diastolic function declined (fractional shortening before the race, 39.6 +/- 0.65%; a

136 milar left ventricular systolic pressure and fractional shortening but more hypertrophy, fibrosis, an

137 ion with reductions in ejection fraction and fractional shortening, but no evidence of heart failure.

138 In the vehicle group, fractional shortening by echocardiography decreased (-23

139 ricular end systolic diameter, and decreased fractional shortening by echocardiography.

140 gnificant improvements in ejection fraction, fractional shortening, cardiac index, LV dP/dt40, LV neg

141 atrial diameter, left ventricular mass, and fractional shortening), carotid-femoral pulse wave veloc

142 sumption led to cardiac hypertrophy, reduced fractional shortening, cell shortening, and impaired int

143 evealed LV dilation, as well as decreased LV fractional shortening (CIH, 29.7+/-9.8%; HC, 37.4+/-7.1%

144 F resulted in a decrease in left ventricular fractional shortening compared with controls (P<0.001).

145 ar dysfunction assessed as percent change in fractional shortening compared with controls.

146 ventricular dilatation and deterioration of fractional shortening compared with placebo-treated mice

147 ography showed the shPHD2 group had improved fractional shortening compared with the shScramble group

148 of ventricular myocyte Ca(2)+ transients and fractional shortening (contraction) and the spontaneous

149 Cardiac performance measured as fractional shortening decreased proportionally with decr

150 hich coincided with decreased left ventricle fractional shortening (-Delta11%; P<0.05) at 7 days post

151 nterstitial collagen, and did not improve LV fractional shortening despite decreased LVES pressure.

152 -systolic dimensions, ejection fraction, and fractional shortening) deteriorated in TNC-deficient mic

153 currents, [Ca2+]i transient amplitudes, and fractional shortening did not differ between nonrejectin

154 local measurements of LV wall thickness and fractional shortening differed from central measurements

155 n challenge, NOS2-deficient mice had greater fractional shortening, dP/dt(max), and Slope(LVESPD) tha

156 ge in left ventricular (LV) mass and percent fractional shortening during Ang II treatment.

157 okine levels, reduced ejection fraction, and fractional shortening (ejection fraction %, 54.76 +/- 0.

158 mice showed preserved ejection fraction and fractional shortening (ejection fraction %, 73.06 +/- 6.

159 hy characterized by significant reduction in fractional shortening, ejection fraction, and a reduced

160 ce (24 months), as evidenced by decreases in fractional shortening, ejection fraction, and cardiac ou

161 diography showed significant improvements in fractional shortening, ejection fraction, and stroke vol

162 diastolic volume, and mass were greater, but fractional shortening, ejection fraction, and the maximu

163 Baseline fractional shortening, ejection fraction, isovolumic rel

164 icant abnormalities in mean left ventricular fractional shortening, end-diastolic dimension, contract

165 howed significant improvement of ventricular fractional shortening, end-systolic dimension, and end-d

166 For example, the mean LV fractional shortening fell by approximately two SD in bo

167 m (P<0.01), with an accompanying increase in fractional shortening from 14+/-7% to 20+/-10% (P=0.05).

168 Doxorubicin decreased left ventricular fractional shortening from 57+/-2% to 47+/-1% (P<0.001)

169 At baseline, SHHF rats had decreased fractional shortening (FS) (31+/-3% versus 67+/-3% in WK

170 myocardial infarction (MI) (left ventricular fractional shortening (FS) = 24 +/- 1%; n = 15) evoked l

171 Mean fractional shortening (FS) and afterload were compared f

172 The steady-state increases in fractional shortening (FS) and peak-systolic [Ca2+]i in

173 Fractional shortening (FS) at echocardiography defined M

174 y demonstrated that Cfz led to a significant fractional shortening (FS) depression in protocols 2 and

175 ociated with increased left ventricular (LV) fractional shortening (FS) during tilt testing, which is

176 o the echocardiogram before left ventricular fractional shortening (FS) improved to 20% and 30% (comp

177 children who, at baseline, had depressed LV fractional shortening (FS) or contractility; increased L

178 In this model, in vivo fractional shortening (FS) remained constant despite HW:

179 During compensated hypertrophy in vivo fractional shortening (FS) remains constant until heart

180 itively related to log-QRS duration, whereas fractional shortening (FS) was inversely related (p < 0.

181 Moreover, tadalafil preserved fractional shortening (FS: 31+/-1.5%) compared to contro

182 ions, corrected ejection time (ETc), percent fractional shortening (%FS), VCFc, and ESSm were determi

183 entricular systolic function (predoxorubicin fractional shortening [FS] 61+/-2%, postdoxorubicin FS 4

184 ed 2 weeks later to evaluate heart function (fractional shortening [FS]), end-diastolic diameter, and

185 , 3.68+/-0.12 mm, n=7; P<0.05) and increased fractional shortening (Gq, 32+/-1%, n=12; Gq/AC, 41+/-2%

186 cAMP-PDE activity caused a ~50% decrease in fractional shortening, hypertrophy, dilatation, and prem

187 ent for posterior wall thickness (ICC=0.65), fractional shortening (ICC=0.64), and septal wall thickn

188 and decreased cardiac ejection fraction and fractional shortening in aged (24-month-old) mice and An

189 ingle dose of 24 Gy caused a 35% increase in fractional shortening in BN rats compared with a 16% inc

190 c studies demonstrated significantly reduced fractional shortening in chimeric mice (26.6+/-2.3% vers

191 eft ventricular wall thickness and decreased fractional shortening in DKO animals.

192 ar function, including ejection fraction and fractional shortening in group 3 (P<0.02) as compared wi

193 nd end-systolic chamber size, with decreased fractional shortening in tamoxifen-treated 2AxMCM mice.

194 significant improvement of left ventricular fractional shortening in the minicircle vector carrying

195 diography showed significant preservation of fractional shortening in the MN group compared to contro

196 so induced functional recovery in myocardial fractional shortening in vivo and preserved contractile

197 3.1(-/-) and WT, except for smaller post-AVB fractional-shortening increase in Cav3.1(-/-).

198 dimension) increased (+10.9+/-1.0%), whereas fractional shortening increased (+17.5+/-4.4%) in NCX an

199 genic male mice had improved heart function; fractional shortening increased by 74%, and diastolic fu

200 Echocardiography revealed decreased fractional shortening, increased end-systolic diameter,

201 Fractional shortening, left ventricular ejection fractio

202 ram, and systolic dysfunction was defined as fractional shortening less than 25%.

203 ac function as measured by echocardiographic fractional shortening (LRS 22.1 and 15.2 respectively, L

204 ystolic dysfunction in both sets of animals (fractional shortening <0.16 by echocardiogram).

205 population, mildly reduced left ventricular fractional shortening (<30%) was more common (36% vs. 3%

206 ricular dimensions and decreases ventricular fractional shortening (measured by high-speed video micr

207 .0111) and a significant increase in midwall fractional shortening (MFS) from 14.3% (2.3) to 16.0% (3

208 er LV mass and wall thicknesses and lower LV fractional shortening, midwall shortening, and stress-co

209 hypertrophy, more chamber dilation, reduced fractional shortening, more fibrosis, and impaired survi

210 the 95% PI was -10% to 8%, indicating that a fractional shortening of 32% measured centrally could be

211 Normal Drosophila have a fractional shortening of 87 +/- 4%, whereas cardiomyopat

212 adrenergic regulation of CaV1.2 current and fractional shortening of cardiomyocytes do not require p

213 nificantly reduced heart rates and decreased fractional shortening of Dicer mutant hearts.

214 heart weight to body weight, greatly reduced fractional shortening of the left ventricle, and lethali

215 Echocardiographic fractional shortening on day 28 was significantly higher

216 ns, there were no significant differences in fractional shortening or contraction or relaxation rates

217 th depressed left ventricular (LV) function (fractional shortening or ejection fraction z-score <-2)

218 estive heart failure, lower left ventricular fractional shortening, or higher left ventricular end-di

219 e corresponding values were -8 versus 0% for fractional shortening (P < 0.0001).

220 rved for ejection fraction (R=0.41), midwall fractional shortening (R=0.51), global circumferential s

221 eart failure (documented by >25% decrease in fractional shortening), rats were randomized to receive

222 +/-0.05 cm) and severely depressed function (fractional shortening reduced from 37% to 26%, P<0.02).

223 The systolic stress versus endocardial fractional shortening relationship was similar in DHF an

224 ls, whereas in children infected with HIV-1, fractional shortening remained significantly lower than

225 pairment in systolic function at a time when fractional shortening remains normal.

226 BP-C(C10mut) displayed significantly reduced fractional shortening, sarcomere shortening, and relaxat

227 e was not significantly related to depressed fractional shortening (shortening of 25 percent or loss)

228 doubling end-systolic elastance and raising fractional shortening similarly in CON-treated and HF he

229 Physiological alterations include decreased fractional shortening, systolic and diastolic dysfunctio

230 xhibited a significantly greater decrease in fractional shortening than athletes who were homozygous

231 and ARVMs from female rats displayed greater fractional shortening than males, and female ARVMs and m

232 d cardiac function mitigating the decline of fractional shortening that is normally seen.

233 mensions that were significantly smaller and fractional shortening that was significantly greater in

234 Heart rate, ejection fraction, fractional shortening, the threshold for opening of mito

235 173.1 +/- 40.1% of B, P = 0.01; and systolic fractional shortening to 180 +/- 29.7% of B, P = 0.01 oc

236 s, LV systolic and diastolic dimensions, and fractional shortening to age, sex, body mass index, bloo

237 re was an inverse relationship of midwall LV fractional shortening to microtubule protein.

238 z scores for fractional shortening transiently improved before fallin

239 fibrosis, ventricular dilation, and reduced fractional shortening, ultimately resulting in overt HF.

240 7+/-0.1 mm; IDN-1965, 4.2+/-0.1 mm; P<0.01), fractional shortening (vehicle, 30.7+/-1.2%; IDN-1965, 3

241 LPS significantly decreased left ventricular fractional shortening, velocity of circumferential short

242 in wild-type mice decreased left ventricular fractional shortening, velocity of circumferential short

243 Midwall LV fractional shortening versus mean LV wall stress in the

244 i) transients (fluo-3, confocal microscopy), fractional shortening (video motion), and L-type Ca2+ cu

245 The mean left ventricular fractional shortening, wall thickness, and thickness-to-

246 constriction model [at 10 wk postprocedure, fractional shortening was 0.31 +/- 0.02 in the mutant (n

247 Mean fractional shortening was 1% smaller in central measurem

248 Preoperatively, fractional shortening was 18.8+/-5.5% in the stentless g

249 sthoracic echocardiography, left ventricular fractional shortening was 47+/-2%, 44+/-1%, and 24+/-2%

250 cted region, at four weeks after infarction, fractional shortening was 75+/-18% and -3+/-15% of basel

251 -1.5 versus 26.7+/-1.8 mm Hg and LV regional fractional shortening was 9.4+/-1.6% versus 3.0+/-0.6% (

252 IDs, LVIDd, increased ejection fraction and, fractional shortening was also observed in the Grx-1(Tg/

253 For neuromuscular disease (n=139), lower LV fractional shortening was associated equally with both e

254 However, LV cardiomyocyte fractional shortening was decreased in MR versus normal

255 Compared with WT mice, fractional shortening was greater in NOS3-/- and less in

256 weeks after beginning doxorubicin treatment, fractional shortening was greater in NOS3-/- than in WT

257 In the GHS group, LV fractional shortening was higher (29+/-2%) and LV peak w

258 In the pacing CHF and GH groups, LV fractional shortening was higher and LV wall stress lowe

259 In the absence of propranolol, the LV fractional shortening was higher in TG compared with NTG

260 In ART+ infants, LV fractional shortening was higher than in ART- infants; g

261 Fractional shortening was improved by rapamycin treatmen

262 Basal and isoproterenol-stimulated fractional shortening was preserved in female transgenic

263 Fractional shortening was preserved in rats treated with

264 Left ventricular fractional shortening was quantified by echocardiography

265 With pacing CHF, LV fractional shortening was reduced (19+/-1 versus 45+/-1%

266 at 6 and 12 weeks of doxorubicin treatment, fractional shortening was reduced (20.7%+/-2.5% versus 3

267 In the untreated pacing CHF group, LV fractional shortening was reduced (21+/-2% versus 47+/-2

268 In the untreated pacing CHF group, LV fractional shortening was reduced and peak wall stress i

269 Reduced fractional shortening was related to impaired contractil

270 tdrug measurements, reduction in left atrial fractional shortening was significantly less at all time

271 Left ventricular fractional shortening was significantly reduced after do

272 At 8 months, fractional shortening was similar in internal and extern

273 of both groups revealed that left ventricle fractional shortening was similar in NADPH oxidase(-/-)

274 Fractional shortening was similarly enhanced (12.2+/-1.2

275 e in left ventricle function, as measured by fractional shortening, was detected in mice infected wit

276 al function, including ejection fraction and fractional shortening, was quantitated 2 wks and 4 wks a

277 s were lower whereas LV contractility and LV fractional shortening were higher when compared to the H

278 ins and declines in LV ejection fraction and fractional shortening were observed eight weeks post inf

279 ntricular (LV) mass index, volume index, and fractional shortening were seen in 48, 48, and 46%, resp

280 ts of left-ventricular ejection fraction and fractional shortening were significantly better (P<0.05)

281 ped pressure per gram as well as endocardial fractional shortening were similar in 4-week AS and cont

282 ar function, including ejection fraction and fractional shortening, were improved in group 3 as compa

283 acing therapy in all outcome measures except fractional shortening, which demonstrated a trend toward

284 6 and a QTL near to the marker D19Mit88) for fractional shortening with a LRS of 34.6 and 26.5 respec

285 ss, decreasing LV dimensions, and increasing fractional shortening with advancing age.

286 se was a marker of an attenuated increase in fractional shortening with aging.

287 cyte Ca(2+) transients and enhanced unloaded fractional shortening with no change in SR Ca(2+) pump c

288 failure (hazard ratio 2.20, P=0.005), lower fractional shortening z score (hazard ratio 1.12 per 1 S

289 shortening Z score, higher left ventricular fractional shortening Z score during follow-up, and grea

290 ansplantation, as was lower left ventricular fractional shortening Z score during follow-up.

291 yopathy, and lower baseline left ventricular fractional shortening Z score were associated with incre

292 art failure, and lower left ventricular (LV) fractional shortening z score were independently associa

293 estive heart failure, lower left ventricular fractional shortening Z score, and cause of DCM (P<.001

294 related to higher baseline left ventricular fractional shortening Z score, higher left ventricular f

295 and greater improvement in left ventricular fractional shortening Z score.

296 1), had less-depressed mean left ventricular fractional shortening z scores (-7.85+/-3.98 versus -9.0

297 Mean fractional shortening z scores measured 3.5 to 6.4 years

298 lower nadir CD4 percentage had lower mean LV fractional shortening z scores, whereas the mean z score

299 er cardiac function (LV contractility and LV fractional shortening z scores; all P = .001) and an inc

300 tively associated with left ventricular (LV) fractional shortening (z-score for difference = 1.07; p